Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2016

Date: December 21, 2016
Pages: 163
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until March 31, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: R61ADF79FA1EN
Leaflet:

Download PDF Leaflet

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) – Pipeline Review, H2 2016, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.

Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 2, 22 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 10 and 1 molecules, respectively.

Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Retinitis Pigmentosa (Retinitis) Overview
Therapeutics Development
Retinitis Pigmentosa (Retinitis) - Therapeutics under Development by Companies
Retinitis Pigmentosa (Retinitis) - Therapeutics under Investigation by Universities/Institutes
Retinitis Pigmentosa (Retinitis) - Pipeline Products Glance
Retinitis Pigmentosa (Retinitis) - Products under Development by Companies
Retinitis Pigmentosa (Retinitis) - Products under Investigation by Universities/Institutes
Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development
Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment
Drug Profiles
Retinitis Pigmentosa (Retinitis) - Dormant Projects
Retinitis Pigmentosa (Retinitis) - Discontinued Products
Retinitis Pigmentosa (Retinitis) - Product Development Milestones
Appendix 156

LIST OF TABLES

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2016
Number of Products under Development for Retinitis Pigmentosa (Retinitis) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Plc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings Inc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corp, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Asklepios BioPharmaceutical Inc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Astellas Pharma Inc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences Inc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici SpA, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Genethon SA, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional SA, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by ID Pharma Co Ltd, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Ionis Pharmaceuticals Inc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by M's Science Corp, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by MeiraGTx Ltd, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Nanovector srl, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Novelion Therapeutics Inc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by RegenxBio Inc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio Inc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Shire Plc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics Inc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Sucampo Pharmaceuticals Inc, H2 2016
Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2016
Retinitis Pigmentosa (Retinitis) - Dormant Projects (Contd..1), H2 2016
Retinitis Pigmentosa (Retinitis) - Discontinued Products, H2 2016 14

LIST OF FIGURES

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2016
Number of Products under Development for Retinitis Pigmentosa (Retinitis) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: